5 results on '"Yoshiyuki Hizukuri"'
Search Results
2. Genome-wide siRNA screening in mouse bone marrow-derived macrophages revealed that knockdown of ribosomal proteins suppresses IL-10 and enhances TNF-α production
- Author
-
Yoshiyuki Hizukuri, Yoshihiko Okamura, Naoyuki Makita, and Yasuhiro Hayashi
- Subjects
Ribosomal Proteins ,0301 basic medicine ,Small interfering RNA ,medicine.medical_treatment ,Bone Marrow Cells ,Mice ,03 medical and health sciences ,Ribosomal protein ,medicine ,Gene Knockdown Techniques ,Animals ,Gene knockdown ,Tumor Necrosis Factor-alpha ,Chemistry ,Macrophages ,General Medicine ,In vitro ,Interleukin-10 ,Cell biology ,Interleukin 10 ,030104 developmental biology ,Cytokine ,Gene Expression Regulation ,Original Article ,Tumor necrosis factor alpha ,Genome-Wide Association Study - Abstract
Macrophages play a central role in the immune response, and their diverse functions are attributed to the spectrum of their functional states. To elucidate molecules involved in modulating the balance between the anti-inflammatory cytokine IL-10 and the pro-inflammatory cytokine TNF-α, we conducted genome-wide siRNA screening. First, we established an siRNA screening system using mouse bone marrow-derived macrophages, which are a suitable model for studying functional states of macrophages in vitro. In the primary screen and the subsequent reproducibility assay, 112 siRNA pools demonstrated enhancement of IL-10 production and 497 siRNA pools suppressed IL-10 production. After a deconvolution assay for IL-10-up-regulating siRNA pools, 8 genes were identified as IL-10 repressors, including Cnot1 and Rc3h1, components of the CCR4-NOT complex known to degrade cytokine mRNAs. On the other hand, siRNA pools targeting ribosomal proteins were frequently found among those that down-regulated IL-10 production and up-regulated TNF-α production. Four pools were assayed using deconvoluted siRNAs and identified as high-confidence hits. Thus, we found that the genome-wide knockdown of 19 ribosomal proteins resulted in decreased IL-10 and increased TNF-α production.
- Published
- 2018
3. A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia
- Author
-
Paul Severson, Maiko Narahara, Yan Ma, Gideon Bollag, Yoshiyuki Hizukuri, Hiroyuki Sumi, Mark J. Levis, Lauren Lee, Ben Powell, and Chao Zhang
- Subjects
Combination therapy ,business.industry ,Immunology ,Myeloid leukemia ,Cell Biology ,Hematology ,Pharmacology ,Biochemistry ,BET inhibitor ,chemistry.chemical_compound ,medicine.anatomical_structure ,Tolerability ,chemistry ,In vivo ,medicine ,Cytotoxic T cell ,Bone marrow ,business ,Quizartinib - Abstract
Background: Acute myeloid leukemia patients with FLT3-ITD mutations have a high risk of relapse and death. FLT3 tyrosine kinase inhibitors such as quizartinib and gilteritinib improve overall survival in relapsed patients, but their efficacy is limited and most such patients die of the disease. This is because even with potent FLT3 inhibition, the disease persists within the bone marrow microenvironment, mainly due to bone marrow stroma activating parallel signaling pathways that maintain pro-survival factors. BET inhibitors suppress pro-survival factors such as c-Myc and Bcl2, but these drugs thus far have shown only limited single-agent clinical potential. PLX51107 is a novel BET inhibitor designed to inhibit BET activity in intermittent daily fashion to allow for greater tolerability. We investigated whether the addition of PLX51107 to potent FLT3 inhibition with quizartinib could overcome the protective effect of the bone marrow stroma through inhibition of c-Myc expression. Methods: We developed a plasma inhibitory activity assay for c-Myc (c-Myc PIA) to assess in vivo efficacy of the PLX51107 in patients and to identify c-Myc-inhibitory doses of the drug. We tested PLX51107 alone and in combination with quizartinib in murine models of AML and against primary FLT3-ITD AML cells co-cultured with human bone marrow stroma. In addition, we analyzed gene expression patterns in the treatment models to explore the basis of any observed synergistic cytotoxic effect. Results: In a murine xenograft model of AML using MV4-11 cells, PLX51107 alone induced suppression of tumor growth in association with a 90% decrease in c-Myc gene expression. The combination of PLX51107 and quizartinib induced complete tumor regression in 5 out of 7 animals after 14 days of treatment (Figure 1). Animals treated with a 5-day course of quizartinib alone displayed tumor regression persisting until day 26 of treatment, while the addition of PLX51107 resulted in tumor regression until day 39. In patients treated with a dose of 120 mg/day of PLX51107, the c-Myc PIA demonstrated a robust suppression of c-Myc expression for roughly 6 hours, returning to baseline between 7 and 9 hours post-treatment (Figure 2). The mean plasma concentration to achieve this inhibition was 3.3 uM, which, accounting for the difference in protein drug binding between plasma and culture medium with 10% FBS, corresponded to a concentration of 250 nM PLX51107 in culture medium. With this same concentration and schedule (i.e., at concentrations and exposure times equivalent to what human patients would experience taking 120 mg daily of PLX51107 and 60 mg daily of quizartinib), the combination induced synergistic cytotoxicity in a series of 10 different FLT3-ITD AML patient blast samples co-cultured with bone marrow stroma (Figure 3). C-Myc RNA and protein were directly suppressed in these primary samples, and ingenuity pathway analysis of RNA expression confirmed that c-Myc associated genes displayed the highest level of down-regulation. Conclusions: These studies suggest that combination therapy with approximately 120 mg/day PLX51107 and 60 mg/day quizartinib will be a more effective therapy for relapsed FLT3-ITD AML than 60 mg/day of quizartinib alone. The combination of FLT3 inhibition and BET inhibition may represent an attractive therapeutic option for FLT3-ITD AML. Disclosures Hizukuri: Daiichi Sankyo Co, Ltd: Employment. Severson:Plexxikon Inc.: Employment. Powell:Plexxikon Inc.: Employment. Zhang:Plexxikon Inc.: Employment. Ma:Plexxikon Inc: Employment. Narahara:Daiichi Sankyo Co, Ltd: Employment. Sumi:Daiichi Sankyo, Inc.: Employment. Bollag:Plexxikon Inc.: Employment. Levis:FUJIFILM: Consultancy, Research Funding; Daiichi Sankyo Inc: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Astellas: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Amgen: Consultancy, Honoraria; Menarini: Consultancy, Honoraria.
- Published
- 2019
4. Involvement of guanylin and GC-C in rat mesenteric macrophages in resistance to a high-fat diet
- Author
-
Paul Emile Poleni, Eri Mutoh, Takashi Miyazawa, Atsushi Okamoto, Kazuyo Senba, Kenichi Yamahara, Yukari Date, Ichiro Okano, Mayumi Furuya, Shuichi Koda, Kenji Kangawa, Mikiya Miyazato, Akira Sawaguchi, Yoshiyuki Hizukuri, Masako Sugiyama, Fumiyo Aoyama, and Sayaka Akieda-Asai
- Subjects
Male ,obesity ,medicine.medical_specialty ,Receptors, Peptide ,Guanylin ,diet resistance ,Receptors, Enterotoxin ,QD415-436 ,Fatty Acids, Nonesterified ,Biology ,Diet, High-Fat ,Biochemistry ,dietary lipids ,Gastrointestinal Hormones ,chemistry.chemical_compound ,Endocrinology ,Downregulation and upregulation ,Internal medicine ,lipid metabolism ,Adipocytes ,medicine ,Animals ,Insulin ,Mesentery ,Gene Knock-In Techniques ,RNA, Messenger ,RNA, Small Interfering ,Natriuretic Peptides ,Receptor ,Beta oxidation ,Triglycerides ,Research Articles ,Cholesterol ,Macrophages ,Lipid metabolism ,Cell Biology ,Guanylate cyclase 2C ,Rats ,Gene Expression Regulation ,Liver ,Receptors, Guanylate Cyclase-Coupled ,chemistry ,Macrophages, Peritoneal ,Perilipin ,Rats, Transgenic ,Oxidation-Reduction ,hormones, hormone substitutes, and hormone antagonists - Abstract
A high-fat diet (HFD) is a well-known contributing factor in the development of obesity. Most rats fed HFDs become obese. Those that avoid obesity when fed HFDs are considered diet resistant (DR). We performed a microarray screen to identify genes specific to the mesenteric fat of DR rats and revealed high expression of guanylin and guanylyl cyclase C (GC-C) in some subjects. Our histologic studies revealed that the cellular source of guanylin and GC-C is macrophages. Therefore, we developed double-transgenic (Tg) rats overexpressing guanylin and GC-C in macrophages and found that they were resistant to the effects of HFDs. In the mesenteric fat of HFD-fed Tg rats, Fas and perilipin mRNAs were downregulated, and those of genes involved in fatty acid oxidation were upregulated, compared with the levels in HFD-fed wild-type rats. In vitro studies demonstrated that lipid accumulation was markedly inhibited in adipocytes cocultured with macrophages expressing guanylin and GC-C and that this inhibition was reduced after treatment with guanylin- and GC-C-specific siRNAs. Our results suggest that the macrophagic guanylin-GC-C system contributes to the altered expression of genes involved in lipid metabolism, leading to resistance to obesity.
- Published
- 2013
5. Prediction of missing enzyme genes in a bacterial metabolic network. Reconstruction of the lysine-degradation pathway of Pseudomonas aeruginosa
- Author
-
Yoshihiro Yamanishi, Susumu Goto, Nobuyoshi Esaki, Yoshiyuki Hizukuri, Tetsuya Sato, Hisaaki Mihara, Motoharu Osaki, Hisashi Muramatsu, and Minoru Kanehisa
- Subjects
chemistry.chemical_classification ,Genetics ,Phylogenetic tree ,Lysine ,Metabolic network ,Cell Biology ,Bacterial genome size ,Biology ,Biochemistry ,Aldehyde Oxidoreductases ,Enzyme Activation ,Metabolic pathway ,Enzyme activator ,Enzyme ,chemistry ,Bacterial Proteins ,Predictive Value of Tests ,Pseudomonas aeruginosa ,Molecular Biology ,Gene ,Biological network ,Transaminases - Abstract
The metabolic network is an important biological network which consists of enzymes and chemical compounds. However, a large number of metabolic pathways remains unknown, and most organism-specific metabolic pathways contain many missing enzymes. We present a novel method to identify the genes coding for missing enzymes using available genomic and chemical information from bacterial genomes. The proposed method consists of two steps: (a) estimation of the functional association between the genes with respect to chromosomal proximity and evolutionary association, using supervised network inference; and (b) selection of gene candidates for missing enzymes based on the original candidate score and the chemical reaction information encoded in the EC number. We applied the proposed methods to infer the metabolic network for the bacteria Pseudomonas aeruginosa from two genomic datasets: gene position and phylogenetic profiles. Next, we predicted several missing enzyme genes to reconstruct the lysine-degradation pathway in P. aeruginosa using EC number information. As a result, we identified PA0266 as a putative 5-aminovalerate aminotransferase (EC 2.6.1.48) and PA0265 as a putative glutarate semialdehyde dehydrogenase (EC 1.2.1.20). To verify our prediction, we conducted biochemical assays and examined the activity of the products of the predicted genes, PA0265 and PA0266, in a coupled reaction. We observed that the predicted gene products catalyzed the expected reactions; no activity was seen when both gene products were omitted from the reaction.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.